bioMérieux - Business Review for the Nine Months Ended September 30, 2009

Net sales for the first nine months of 2009 amounted to €895 million, an increase of 7.8% at constant exchange rates and scope of consolidation (like-for-like). Including the growth generated by recent business development agreements, the increase amounted to 11.2%.

The influenza A (H1N1) pandemic had a positive impact on sales, particularly of QuickVue® Influenza tests and NucliSENS® easyMAG® instruments. Excluding this impact, like-for-like growth was an estimated 6.7% over the first nine months and 9% in the third quarter alone.

2009 Nine-Month Sales

• up 7.8% at constant exchange rates and scope of consolidation
• up 11.2% at constant exchange rates, including business development agreements

Download the Complete Press Release: